Literature DB >> 16613963

Systemic lupus erythematosus.

David P D'Cruz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16613963      PMCID： PMC1440614          DOI： 10.1136/bmj.332.7546.890

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  25 in total

1.  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise.

Authors:  C M Tench; J McCarthy; I McCurdie; P D White; D P D'Cruz
Journal:  Rheumatology (Oxford)       Date:  2003-04-16       Impact factor: 7.580

2.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

3.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

4.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

5.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

6.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

7.  Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women.

Authors:  Masoud El-Magadmi; Helena Bodill; Yasmeen Ahmad; Paul N Durrington; Michael Mackness; Michael Walker; Robert M Bernstein; Ian N Bruce
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

Review 8.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Features associated with epilepsy in the antiphospholipid syndrome.

Authors:  Yehuda Shoenfeld; Shaul Lev; Ilan Blatt; Miri Blank; Joseph Font; Philipp von Landenberg; Nirit Lev; Joseph Zaech; Ricard Cervera; Jean-Charles Piette; Munther A Khamashta; Maria L Bertolaccini; Graham R V Hughes; Pierre Youinou; Pierre Luigi Meroni; Vittorio Pengo; J Delgado Alves; Angela Tincani; Gyula Szegedi; Gabriella Lakos; Gunnar Sturfelt; Andreas Jönsen; Takao Koike; Marielle Sanmarco; Amelia Ruffatti; Zdenka Ulcova-Gallova; Sonja Praprotnik; Blaz Rozman; Margalit Lorber; Joab Chapman; Peter J C van-Breda-Vriezman; Jan Damoiseaux
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

10.  High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Maria-Victoria Egurbide; Jon Ugalde; Ciriaco Aguirre
Journal:  Arch Intern Med       Date:  2004-01-12
View more
  11 in total

1.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

Review 2.  Systemic lupus erythematosus.

Authors:  Lucy H Mackillop; Sarah J Germain; Catherine Nelson-Piercy
Journal:  BMJ       Date:  2007-11-03

3.  Increased postpartum thyroxine replacement in Hashimoto's thyroiditis.

Authors:  Juan C Galofré; Richard S Haber; Adele A Mitchell; Rachel Pessah; Terry F Davies
Journal:  Thyroid       Date:  2010-08       Impact factor: 6.568

4.  Extrarenal Immune-Mediated Disorders Linked with Acute Poststreptococcal Glomerulonephritis: a Systematic Review.

Authors:  Elena A Bertola; Giacomo D Simonetti; Rosaria Del Giorno; Olivier Giannini; Emilio F Fossali; Martina Meoli; Mario G Bianchetti; Benedetta Terziroli Beretta-Piccoli; Gregorio P Milani
Journal:  Clin Rev Allergy Immunol       Date:  2019-10       Impact factor: 8.667

5.  B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?

Authors:  Omer Karadag; Meral Calguneri; Bunyamin Yavuz; Enver Atalar; Ali Akdogan; Umut Kalyoncu; Sedat Kiraz; Serdar Aksoyek; Ferhan Ozmen; A Ihsan Ertenli
Journal:  Clin Rheumatol       Date:  2007-02-21       Impact factor: 2.980

6.  Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation.

Authors:  Jonathan A Deane; Prapaporn Pisitkun; Rebecca S Barrett; Lionel Feigenbaum; Terrence Town; Jerrold M Ward; Richard A Flavell; Silvia Bolland
Journal:  Immunity       Date:  2007-11-08       Impact factor: 31.745

7.  Ebola virus infection induces autoimmunity against dsDNA and HSP60.

Authors:  H Fausther-Bovendo; X Qiu; S McCorrister; G Westmacott; P Sandstrom; C Castilletti; A Di Caro; G Ippolito; G P Kobinger
Journal:  Sci Rep       Date:  2017-02-09       Impact factor: 4.379

Review 8.  Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders.

Authors:  Thomas A Pollak; Jonathan P Rogers; Robert G Nagele; Mark Peakman; James M Stone; Anthony S David; Philip McGuire
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

9.  Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.

Authors:  D A Roth; A Thompson; Y Tang; A E Hammer; C T Molta; D Gordon
Journal:  Lupus       Date:  2015-09-18       Impact factor: 2.911

10.  Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.

Authors:  A Babini; A M Cappuccio; C Caprarulo; G Casado; A Eimon; H Figueredo; M A García; S Magri; P Mannucci; S Perez Rodriguez; B A Pons-Estel; E J Velozo; M Iglesias-Rodriguez; G Streger
Journal:  Lupus       Date:  2020-08-14       Impact factor: 2.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.